Greg Chopskie

Partner | Intellectual Property

About

Acknowledged nationally for his expertise in corporate intellectual property and patent litigation, Greg brings over 25 years of experience advising global, multibillion-dollar pharmaceutical companies. He received a recommendation from The Legal 500 US in 2017 for Patent Litigation, as well as recognition as a Corporate IP Star in 2016 by Managing Intellectual Property.

  • As in-house counsel, Greg successfully developed and implemented litigation, prosecution, and regulatory strategies to confront generic competitors, and provided a comprehensive analysis of ongoing patent litigation and exclusivity strategies. He has significant experience in counseling c-suite executives on global IP strategy, patent portfolio programs, and high-stakes litigation. In addition, Greg has experience in due diligence; IP transactions; international commercial transactions; and international competition matters.

    Greg’s experience includes several in-house roles, which involved IP and general commercial litigation, drafting and negotiating commercial agreements, and employment disputes. As former associate general counsel to a global, research-based biopharmaceutical fortune 500, he guided the company through several multibillion-dollar litigations, favorably resolving several disputes. He advised executives on legal strategy and litigation, leveraging the legal department to both minimize liability and drive business growth.

Practices

  • IP Litigation and Enforcement

  • IP Transactions and Licensing

  • Patents

  • Trade Secrets

Admissions

  • California

  • Virginia

  • District of Columbia

  • U.S. Patent and Trademark Office

Education

  • George Mason University School of Law, J.D., cum laude, 1999

  • Georgetown University, B.S., 1992

Awards and Honors

  • Recommendation from The Legal 500 US in 2017 for Patent Litigation

  • Named a Corporate IP Star in 2016 by Managing Intellectual Property

Law Firm Experience

  • Squire Patton Boggs

  • Morrison & Foerster

  • Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

Corporate Experience

  • Gilead Sciences, Inc.

  • Shionogi, Inc

  • Wyeth

Representative Transactions

Protonix® Litigation

  • Protonix ($2.5b/year) experienced the largest at-risk launch by a generic competitor in history. Working closely with senior executives, was part of a team that devised a comprehensive response that minimized loss in market share while, concurrently, devised a litigation strategy that recovered wyeth’s damages after a trial.

FTC Litigation

  • FTC ($10b/year), a critical component in HIV combination therapy, faced a significant patent challenge from a generic competitor. Oversaw in-house and outside counsel developing strategy and tactics for trial. After trial, we forced a favorable settlement that provided sufficient runway to launch second-generation products.

Harvoni® Litigation

  • Harvoni ($12b/year), the first complete treatment for hepatitis c, represented a substantial improvement in short-term therapies. Abbvie, an innovator competitor, obtained several patents that purported to cover Harvoni in over 30 different countries. Oversaw a team of international in-house and outside counsel to design and implement a global response to AbbVie’s threat. After contentious proceedings around the world, AbbVie agreed to license Gilead the relevant patents for a single, immaterial payment amount.